Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies through PLK1 inhibition [3] Group 1: Upcoming Conferences - Company management will participate in three investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference on March 4, Barclays 28th Annual Global Healthcare Conference on March 10, and Leerink Partners Global Healthcare Conference on March 11 [2] Group 2: Company Overview - Cardiff Oncology's lead asset, onvansertib, is a specific oral PLK1 inhibitor currently in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), targeting a large, underserved patient population [3] - Onvansertib is also being investigated in other PLK1-driven cancers through ongoing investigator-initiated trials and has demonstrated robust clinical activity in difficult-to-treat tumors [3] - The company's goal is to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients [3]